Prostate cancer exhibits wide clinical heterogeneity, ranging from indolent tumours that progress slowly over decades to aggressive variants that metastasize within months. The distinction between these phenotypes is determined by a combination of cellular differentiation patterns, genetic mutations, and molecular markers—not by chance or chance alone. Understanding what drives aggressiveness is essential for clinicians tailoring treatment intensity and for patients navigating prognosis and care options.
Key takeaways
- Prostate cancer aggressiveness is classified using the Gleason grading system, which stratifies tumours into five grades based on cell morphology
- Aggressive prostate cancers harbour specific genetic alterations (PTEN loss, TP53 mutations, BRCA2 defects) that correlate with poor outcomes and treatment resistance
- Grade Groups (I–V) used in modern clinical practice offer better prognostic accuracy than Gleason score alone and guide decisions on active surveillance versus radical therapy
How pathologists define aggressive cancer
The Gleason grading system, established in 1966 and refined in 2005, remains the gold standard for assessing prostate cancer differentiation. Pathologists examine prostate tissue under a microscope and assign grades (1–5) based on how much the cancer cells deviate from normal prostate gland architecture. A Gleason score is the sum of the two most common grades found in a tumour, ranging from 2 to 10.
Aggressive cancers typically score 8–10 (also termed “poorly differentiated” or “undifferentiated”). According to the American Cancer Society and the National Cancer Institute, higher Gleason scores strongly predict shorter time to metastasis and reduced overall survival. A tumour with a Gleason score of 9–10 may progress to metastatic disease within 3–5 years if left untreated, whereas a Gleason 6 tumour may remain clinically silent for 15+ years.
Prostate cancer risk stratification by Grade Group
Five-year biochemical recurrence-free survival rates by Grade Group classification
Source: American Cancer Society, NCCN Clinical Practice Guidelines (2024) | Georgian Medical Journal News
Genetic mutations underlying aggressive phenotypes
Beyond histological grading, genetic alterations drive prostate cancer aggressiveness at the molecular level. Tumours with loss of the PTEN tumour suppressor gene are significantly more likely to progress to metastatic disease. According to research published in molecular oncology journals, PTEN-deficient prostate cancers activate the PI3K/AKT/mTOR pathway, promoting cell proliferation and survival even under therapeutic stress.
Mutations in TP53 (the “guardian of the genome”) are found in approximately 50% of metastatic castration-resistant prostate cancers and only 5% of localized tumours. This stark difference indicates that TP53 loss is a driver of aggressive, hormone-resistant disease. Similarly, BRCA2 mutations—originally identified in breast cancer predisposition—confer heightened risk of aggressive prostate cancer and poor response to conventional androgen deprivation therapy.
For deeper context on cancer genomics, see our New Studies section for recent discoveries in tumour mutation profiling.
Clinical implications: from diagnosis to treatment strategy
Modern prostate cancer management stratifies patients into risk groups to guide intensity of treatment. The National Comprehensive Cancer Network (NCCN) classifies prostate cancer as very low risk, low risk, intermediate risk, high risk, and very high risk based on Gleason grade group, PSA level, and tumour stage. Aggressive cancers (Grade Groups IV–V) automatically fall into high or very high risk categories and typically warrant radical prostatectomy, external-beam radiation therapy, or multimodal approaches including systemic therapy.
Conversely, Grade Group I tumours (Gleason score ≤6) in men with long life expectancy and low PSA are candidates for active surveillance—regular monitoring without immediate surgery or radiation. This risk-stratified approach, endorsed by the National Cancer Institute, balances cancer control against overtreatment and quality-of-life considerations. For clinicians and patients seeking guidance on treatment options, refer to our Clinical Updates for the latest therapeutic advances.
Aggressive prostate cancer is defined not by a single factor, but by the convergence of poor histological differentiation (Gleason 8–10), specific genetic alterations (PTEN loss, TP53 mutations, BRCA2 defects), and rapid clinical progression. Modern Grade Groups provide superior prognostic accuracy and guide individualized treatment intensity.
— Based on American Cancer Society guidelines and molecular oncology literature
What this means
Frequently asked questions
What is the difference between Gleason score and Grade Group?
The Gleason score (2–10) sums the two most prevalent tumour grades under microscopy. Grade Groups (I–V), introduced in the 2014 International Society of Urological Pathology (ISUP) consensus, collapse Gleason scores into five tiers and offer superior prognostic stratification. Grade Group I (Gleason ≤6) has >95% five-year recurrence-free survival; Grade Group V (Gleason 9–10) has
Can a man have aggressive prostate cancer with a normal PSA level?
Yes, although uncommon. PSA (prostate-specific antigen) reflects tumour burden and secretory function, but high-grade cancers may produce less PSA or grow rapidly before PSA elevation occurs. This underscores why biopsy is sometimes necessary even with borderline PSA levels if clinical suspicion is high or imaging abnormalities are present.
Are genetic mutations like BRCA2 hereditary?
Yes. BRCA2 mutations are inherited in an autosomal dominant pattern; men carrying a BRCA2 mutation have a lifetime prostate cancer risk of ~40% and higher likelihood of aggressive disease. Families with a history of early-onset prostate or breast cancer should discuss genetic counselling and testing with their physicians.
As our understanding of prostate cancer biology deepens through genomic research and clinical trials, the field is moving toward increasingly personalized approaches to risk assessment and treatment selection. Men diagnosed with aggressive prostate cancer now have access to more precise prognostic tools and targeted therapies than ever before, though outcomes remain contingent on early detection and timely, evidence-based intervention. Ongoing investment in molecular pathology training and equitable access to genomic profiling will be critical to improving outcomes across all populations.
Source: Jeremy Clarkson has aggressive prostate cancer. What makes some cancers more aggressive than others?
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
